Theravance Biopharma (TBPH) Announces Significant Data from Pivotal Phase 3 FULFIL Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Theravance Biopharma Highlights Positive Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva at ERS International Congress
September 7, 2016 5:03 PM EDTDUBLIN, IRELAND -- (Marketwired) -- 09/07/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH)
Statistically Significant Benefits in Lung Function, Health-Related Quality of Life and Annual Rate of Exacerbations Observed for Closed Triple as Compared to Symbicort Turbohaler
Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement With Innoviva
GSK's Regulatory Submissions on Track for the Closed Triple in U.S. and Europe by end of 2016
Theravance Biopharma, Inc. (NASDAQ: TBPH) (Theravance Biopharma) today announced that... More
